Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Altimmune, Inc. insider Christophe Arbet-Engels, the company's Chief Medical Officer, reported awards on 10/01/2025 consisting of 450,000 stock options with a $3.87 exercise price and 150,000 restricted stock units (RSUs). The options vest over four years with 25% vesting on 10/01/2026 and the remainder monthly over the next 36 months, subject to continued service. The RSUs vest over four years with 25% on 10/01/2026 and the remainder in annual installments over three years and have no expiration date. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Altimmune, Inc. (ALT) filed a Form 3 reporting that Christophe Arbet-Engels, serving as Chief Medical Officer and an officer/director, has no securities beneficially owned in the company as of the event date 10/01/2025. The filing notes a Power of Attorney (Exhibit 24) and is signed by Gregory Weaver, as Attorney-in-Fact on 10/03/2025. This is an initial ownership statement required by Section 16; it discloses the reporting person’s relationship to the issuer and that no equity or derivative holdings are reported on the form.
Altimmune, Inc. reported a planned leadership transition in its medical organization. Former Chief Medical Officer Dr. Scott Harris has entered into a Transitional Services and Release Agreement and stepped down from the CMO role effective October 1, 2025, becoming Senior Strategic Advisor through his previously announced retirement date of February 28, 2026. The company has appointed Christophe Arbet-Engels, MD, PhD as the new Chief Medical Officer, effective October 1, 2025.
During the transition period, Dr. Harris will help transfer responsibilities and continue as an employee, receiving his current salary and benefits, continued vesting of outstanding equity awards through the separation date, an extension of his stock option exercise period to 12 months after separation, and eligibility for a full 2025 cash bonus, all conditioned on a release of claims and compliance with customary covenants.
Catherine A. Sohn, a director of Altimmune, Inc. (ALT), was granted stock options covering 48,800 shares with an exercise price of $3.92. The options become vested and exercisable in substantially equal monthly installments over the 12 months following the 09/25/2025 grant date, and they expire on 09/25/2035. After the grant the reporting person beneficially owns 48,800 option shares on a direct basis. The grant is an equity-based director compensation intended to align interests with shareholders; if exercised it will convert into common stock.
Altimmune, Inc. (ALT) director Jerome Benedict Durso was granted stock options on 09/25/2025 to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The options become exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. Following the grant, Durso beneficially owns 48,800 options. The Form 4 was filed by a single reporting person and signed by an attorney-in-fact on 09/29/2025.
Altimmune, Inc. (ALT) director Teri L. Lawver received a stock option grant on 09/25/2025 to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following 09/25/2025, subject to continued service, and expires on 09/25/2035. Following the reported transaction, the reporting person beneficially owns 48,800 option shares. The Form 4 was signed by an attorney-in-fact on 09/29/2025.
Diane Jorkasky, a director of Altimmune, Inc. (ALT), received a grant of stock options on 09/25/2025. The Form 4 shows an award of 48,800 stock options with an exercise price of $3.92 per share and an expiration date of 09/25/2035. The options were reported as acquired and are held directly by the reporting person. The shares underlying the option vest in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. The filing was signed by Gregory Weaver as Attorney-in-Fact on 09/29/2025.
Altimmune insider activity: Director John Gill reports three items: a previously made bona fide gift of 2,714 shares of common stock, a correction that he currently holds zero shares directly or indirectly, and an option award for 48,800 shares with an exercise price of $3.92. The option was granted on the reported transaction date and vests monthly over 12 months beginning after the grant, with an exercise term extending roughly ten years from the grant date. The filing clarifies prior reporting errors that overstated his direct holdings by 57 shares and documents that the shares underlying the option are exercisable upon vesting.
Altimmune, Inc. (ALT) director Klaus Schafer reported receipt of a stock option award on 09/25/2025 that grants the right to buy 48,800 shares of common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to continued service, and expires on 09/25/2035. Following the reported transaction, the reporting person beneficially owns 48,800 option shares directly. The filing was submitted via counsel and signed by an attorney-in-fact on 09/29/2025.
Altimmune director Mitchel Sayare was granted an option to purchase 48,800 shares of common stock at a $3.92 exercise price. The option was granted on 09/25/2025, becomes exercisable in substantially equal monthly installments over the 12 months following that date, and expires on 09/25/2035. The reporting on Form 4 indicates the position is held directly. The filing is signed by an attorney-in-fact on behalf of the reporting person.